Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory MM (r/r MM) displaying lower sensitivity to daratumumab. ISB 1342 is a...
Asıl Yazarlar: | Pouleau, B, Estoppey, C, Suere, P, Nallet, E, Laurendon, A, Monney, T, Pais Ferreira, D, Drake, A, Carretero-Iglesia, L, Macoin, J, Berret, J, Pihlgren, M, Doucey, M-A, Gudi, GS, Menon, V, Udupa, V, Maiti, A, Borthakur, G, Srivastava, A, Blein, S, Mbow, ML, Matthes, T, Kaya, Z, Edwards, C, Edwards, JR, Menoret, E, Kervoëlen, C, Pellat-Deceunynck, C, Moreau, P, Zhukovsky, E, Perro, M, Chimen, M |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
American Society of Hematology
2023
|
Benzer Materyaller
-
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Yazar:: Grandclément, C, ve diğerleri
Baskı/Yayın Bilgisi: (2024) -
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Yazar:: C. Grandclément, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01) -
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Yazar:: Carretero-Iglesia, L, ve diğerleri
Baskı/Yayın Bilgisi: (2024) -
P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
Yazar:: C. Grandclement, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01) -
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
Yazar:: Jeremy Loyau, ve diğerleri
Baskı/Yayın Bilgisi: (2025-12-01)